摘要 |
<p>The present invention is directed to a substituted pyrimidine compound of formula (I) as set forth herein, or an enantiomer thereof, or a prodrug or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising such a compound. The invention also includes a method of treatment of a patient by the administration of a pharmaceutically effective amount of such a compound. Formula (I), wherein m and n, independently of each other, are selected from the integers 0, 1, 2 or 3; X and Y, independently of each other, are selected from CR1R2, NR1 or O, wherein X and Y cannot both be O; or X and Y, taken together with the bond between them, form a phenyl group optionally substituted by one to four R3 groups; each Z, independently of each other, is CR1R2; R1, R2 and R3, independently of each other, are selected from the group consisting of H, halogen, aryl, amino, optionally substituted alkyl, optionally substituted alkoxy, and carboxy; wherein optionally substituted alkyl, may be substituted by one to three of the same or different of halogen, carboxy, cyano, hydroxy, amino or aryl.</p> |
申请人 |
AVENTIS PHARMACEUTICALS INC. |
发明人 |
HARRIS, KEITH J.;AGUIAR, JOACY C.;SHUM, PATRICK WAI-KWOK;ZHAO, ZHICHENG;POLI, GREGORY B.;STOKLOSA, GREGORY;CHOI-SLEDESKI, YONG-MI;REILING, STEPHAN;STEFANY, DAVID;GARDNER, CHARLES |